Independent consulting that turns Citeline’s trial, site and real-world data into a clear recommendation for your study
Our experts use Citeline’s trial, site and patient data, and AI-driven analysis to drive recommendations for feasibility, shape protocols, plan recruitment and choose the right sites.
57% more trial coverage than public registries capture, plus linked real-world patient data.
Experts who read the data in the context of your indication — not a dataset to interpret yourself.
We don't run trials or operate sites, so sponsors use us to pressure-test plans from elsewhere.
From a single country assessment to a full strategy. The analysis stops when your question is answered.
curated trials
sites across 185 countries
clinical intelligence
validated accuracy
more coverage than public registries
Scoped to a specific question, delivered as a recommendation — not a raw data extract
Protocol, country, and site feasibility, grounded in real trial performance and patient data.
Plan for a diverse, representative trial population, with evidence-based targets and the site strategy to deliver them.
Expert analysis of integrated real-world data, delivered as recommendations, not an extract.
Eligibility, endpoints, and design tested against comparable trials and real patients.
Competitive and pipeline assessment showing concentration, competition, and white space.
Disease burden, prevalence, and patient distribution to underpin strategy and country selection.
Prioritized recommendations built from patient access and trial experience, not familiarity.
Curated data assembled around your question, delivered analysis-ready for your teams.
Citeline and real-world data visualized for your indication, refreshed on an agreed cadence.
Feasibility as a Service answers three connected questions across protocol, country, and site.
| Feasibility type | Question it answers | What we do |
|---|---|---|
| Protocol feasibility | Is this protocol realistically recruitable as written? | We develop and pressure-test your inclusion and exclusion criteria to establish the clinically and demographically relevant patient landscape, and whether your requirements can realistically be recruited. |
| Country feasibility | Where should this study run? | We analyze competitive trials, study timelines, enrollment metrics, protocol-matched patient populations, and geographic distribution to inform country selection. |
| Site feasibility | Which sites should we prioritize? | We prioritize sites within your selected countries on protocol-matched patient availability, relevant trial experience, and limited competitive trial engagement. |
5 stages, from a no-cost scoping conversation through to follow-through into execution
We work through the decision you face, your timeline, and what evidence would change your mind.
We define the questions, the data, the deliverable and timeline, and confirm which experts lead.
Our analysts query Citeline and real-world patient data, interpreted against your study context.
Findings presented with the reasoning, data, and assumptions, so your team can interrogate them.
Where the decision moves into execution, the same insight carries into our platform solutions.
| Consideration | In-house | Your CRO | Citeline C&A RECOMMENDED |
|---|---|---|---|
| Underlying data | Public registries, missing trials no public source captures | Its own operational history — thin outside it | 60,000+ sources, 199,000+ sites, linked real-world patient data |
| Independence | Exposed to assumptions already held inside the team | The party recommending the plan is paid to deliver it | No stake in the operational outcome |
| Therapeutic expertise | Deep in familiar areas, limited entering a new one | Varies by the team assigned to your account | Analysts matched to your therapeutic area |
| Patient-level evidence | Rarely available; licensing is a separate exercise | Usually site-reported, not drawn from patient data | Protocol-matched populations from linked claims, lab, and EMR |
| Speed | Constrained by capacity and competing priorities | Tied to the contracting cycle and its queue | A discrete engagement with an agreed timeline |
| What you receive | An analysis only as strong as the data behind it | A proposal framed around a delivery model | A recommendation with reasoning and assumptions exposed |
| After the decision | Execution planned separately | Continuity, on the CRO's terms | Carries into site selection, recruitment, and our platform |
Citeline Consulting & Analytics helped a CRO with writing clinical trial diversity action plans and expanding its expertise in additional therapeutic areas.
Citeline Consulting & Analytics helps sponsors and CROs plan better trials. Our analysts combine Citeline’s trial, site and investigator data, linked real-world patient data, and AI-powered insights to answer your toughest questions on feasibility, protocol design, site selection, and representative enrollment.
Our consultants use Citeline’s expert-curated data on clinical trials, sites, and investigators worldwide, including real enrollment performance. We combine this with linked real-world patient data, including claims, EHR, lab and prescription records, and AI-powered insights.
Yes. Recommendations are delivered with the data, the reasoning, and the assumptions behind them, so your team can interrogate the conclusion and defend it internally.
Yes. Engagements operate under confidentiality terms agreed before work begins, and your protocol and study information are never used outside your engagement.
Where you want to act on it, the same intelligence carries into our site selection, recruitment, and platform products, so the move from planning into execution does not restart from scratch.
Book a demo, explore AI solutions, or speak to an expert. Tell us what you're working on and our team will be in touch shortly.
